Navigation Links
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
Date:9/3/2007

Ranbaxy will benefit from the 180 day shared exclusivity on the product

PRINCETON, N.J., Aug. 30 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL), announced today that the Company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Galantamine Hydrobromide Tablets, 4mg (base), 8mg (base), and 12mg (base). Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Total annual market sales for Razadyne were $130.0 million (IMS - MAT: June 2007).

"This tentative approval will provide Ranbaxy Pharmaceuticals Inc. (RPI) with an opportunity to market this product and anticipate sharing in the period of 180 days exclusivity that will be beneficial to the Company, as well as to the U.S. healthcare system. We will launch the product upon final approval, which is anticipated on December 14, 2008. At the time of launch, product will be available immediately to all classes of trade," according to Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. RANBAXY - enters anti-AIDS segment
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Ranbaxy gets US FDA approval for Lisinopril
4. Ranbaxy Labs Entry Into Anti-Acne Market
5. Ranbaxy trying to make inroads in herbal drugs market
6. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
7. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
8. Ranbaxy opens Drug discovery centre in Gurgaon
9. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
10. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
11. SRL Ranbaxy offers quicker bird flu diagnostic test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... May 30, 2015 The IRS released ... 2015, announcing that, “criminals used taxpayer-specific data acquired from ... approximately 100,000 tax accounts through IRS’ “Get Transcript” application. ... and street address.” , “You don’t even have ... to think it was only a matter of time, ...
(Date:5/29/2015)... Montclair, NJ (PRWEB) May 30, 2015 ... and ever changing local and federal regulations, we ... needs of their patients who are suffering from ... regulations,” says Srinivas Nalamachu, MD, professor of rehabilitation ... Research Institute in Overland Park, Kansas. , A ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 Ready to ... it’s important for all drivers to get their vehicles ready. ... to be prepared. Advanced Driving Systems (ADS) is ready to ... tips on preparing for summer road trips. , When planning ... the following to ensure that the trip goes smoothly and ...
(Date:5/29/2015)... The science of hair restoration has ... to the efforts of internationally recognized hair transplant surgeon ... ARTAS hair restoration and manual FUE techniques to ... anywhere. , A Follicular Unit Extraction (FUE) ... follicle grafts from the donor areas of a patient. ...
(Date:5/29/2015)... Island (PRWEB) May 29, 2015 The ... 2015. The event, now closed to new registration, starts ... Adams. This exciting competitive running event demonstrates the ... to create a public benefit – in this case, ... coastal views around the famed Ocean Drive and passes ...
Breaking Medicine News(10 mins):Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 4Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 5Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 3Health News:Los Angeles and Beverly Hills Hair Transplant Doctor Now Combines Robotic Hair Restoration (ARTAS) and Manual FUE Transplants for Maximum Hair Coverage 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3
... New figures on assisted reproduction technology (ART) in Europe ... use of ICSI (intracytoplasmic sperm injection) to treat infertility, ... Human Reproduction and Embryology (ESHRE) in Barcelona heard today ... using the procedure too often. , In 2005 ...
... Alexandria, Va.A study conducted in Sweden found that more than ... from cancer four or five years earlier reported they were ... they heard this information during the last week of her ... immediately when a wife,s cancer is incurable, including 71 percent ...
... the United States Senate,failed to pass the "Medicare ... a result, a 10.6 percent cut in Medicare ... on July 1, leaving the,physician-patient relationship in great ... Release, go to:, http://www.prnewswire.com/mnr/osteopathic/33934/ , The American ...
... Validates Use of Pharos Innovation,s Proprietary,Device-Free Remote Monitoring Platform to ... ... Medical Costs, NORTHFIELD, Ill., July 8 ... clinical and financial,performance improvement through a device-free remote monitoring platform,announced ...
... an inherent risk in cancer research, particularly in ... misleading results can be mitigated if researchers use ... according to a commentary in the July 8 ... National Cancer Institute . Additionally, the impact of ...
... Help to Lower Health Care Costs, ... Pennsylvania Economy, PITTSBURGH, July 8 The chief ... today at the first,Pennsylvania Insurance Department public hearing about ... be good for customers, health care,providers, and the communities ...
Cached Medicine News:Health News:Researcher say that ICSI may be over-used in some countries 2Health News:Researcher say that ICSI may be over-used in some countries 3Health News:Study finds that significant proportion of men told wife's cancer was incurable late or not at all 2Health News:Audio: Medicare Cuts Threaten Access to Health Care for Seniors 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 3Health News:Awareness of epidemiology's limitations could reduce impact of false-positive cancer results 2Health News:Highmark and Independence Blue Cross CEOs Say Combination of Highmark and Independence Blue Cross will Provide $1 Billion in New Resources Over Six Years 2
(Date:5/29/2015)... 2015  Epic Sciences announced today that the company ... castrate resistant prostate cancer patients, at the 2015 ... Oncology. This application expands the investigational utility of ... platform to characterize circulating tumor cell (CTC) genomic ... have heterogeneous clonal CTC populations harboring separate genetic ...
(Date:5/29/2015)... May 29, 2015 Educating the community ... Association for the Advancement of Wound Care (AAWC), ... support from AAWC,s corporate partners, the Association provides ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ . ... pathway with links to various CME/CEU educational programs. ...
(Date:5/28/2015)... NEW YORK , May 28, 2015 ... billions developing new drugs and tests, and ... for the instruments that can assist them. This ... research publisher. Kalorama Information said instruments such as ... can assist in the identification of drug ...
Breaking Medicine Technology:Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3The Association for the Advancement of Wound Care Educates the Public 2Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3
... data,supporting the clinical development of telaprevir (VX-950), one ... the,treatment of hepatitis C virus (HCV) infection, will ... European Association for the,Study of the Liver (EASL) ... to telaprevir have been accepted for presentation,at the ...
... meeting of the European,Association for the Study of ... /PRNewswire-FirstCall/ --,Schering-Plough Corporation reaffirms its commitment to advancing,the ... (HCV),infection with several key data presentations at the ... 42nd annual meeting,in Barcelona, Spain, April 11-15. A ...
Cached Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 2Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 3Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 4Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 5Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 7
... providing excellence in Ambulatory ECG Monitoring ... physicians in the diagnosis and treatment ... each year. State-of-the-art equipment and technology ... highest standard of customer service makes ...
... is an e-health service developed by ... Telemedicine patient monitoring devices. Designed ... monitoring devices, AerotelNet.com improves patient and ... advanced communication capabilities make it easy ...
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Medicine Products: